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Purpose: Current advances in our understanding of tumor immune escape leads 
to new field of immunotherapy in cancer treatment, including head and neck 
squamous cell carcinoma (HNSCC). However, still only a fraction of patients 
respond to anti-PD-1/PD-L1 monoclonal antibodies (mAbs). In this study, we 
investigated the effects of MEK inhibitor trametinib on the expression of 
immune-associated molecules, MHC class I, PD-L1 and T-cell recruiting 
chemokines, CXCL9 and CXCL10, in human HNSCC cell lines. Then, we 
assessed the therapeutic efficacy of trametinib combined with an anti-PD-L1 
mAb in vivo, using SCCVII mouse syngeneic tumor model for HNSCC. 
Methods: Six human HNSCC cell lines (SNU-1041, SNU-1066, SNU-1076, 
Detroit 562, FaDu and HN31) and a mouse squamous cell carcinoma cell line 
(SCCVII) were used. We conducted MTT cell viability assay using these cell 
lines after treatment with trametinib for 72 hours. MHC class I and PD-L1 
expression levels were analyzed by flow cytometry after treatment with 
trametinib and/or interferon-gamma (IFN-γ). Expression of PD-L1, Erk1/2, 
STAT1, STAT2, STAT3, STAT5 and STAT6 were analyzed by Western 
blotting. STAT1, STAT3 and STAT6 were knocked down by siRNA 
transfection using lipofectamine. To determine the levels of CXCL9 and 
CXCL10 transcripts after trametinib treatment, quantitative real-time PCR was 
carried out. Protein levels of CXCL9 and CXCL10 were determined using 
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ELISA and intracellular flow cytometry. We evaluated the combinatorial 
therapeutic effect of MEK inhibitor and an anti-PD-L1 mAb in syngeneic 
mouse SCCVII squamous cell carcinoma model. 
Results: The growth inhibition by trametinib was variable between cell lines 
with moderate sensitivity (10 nM < IC50 < 100 nM in four of six human cells). 
IC50 values were over 10 μM in Detroit 562 and FaDu. Trametinib upregulated 
MHC class I and PD-L1 expression in human HNSCC cell lines, and this 
occurred via STAT3 activation. Trametinib also further upregulated the 
increase in CXCL9 and CXCL10 expression caused by IFN-γ in HNSCC cells, 
which is associated with T cell infiltration in tumor tissues. Finally, we 
evaluated the therapeutic efficacy of trametinib combined with an anti-PD-L1 
mAb in vivo, using SCCVII mouse syngeneic tumor model for HNSCC. While 
neither PD-L1 blockade nor trametinib treatment alone affected tumor growth, 
the combined therapy significantly delayed tumor growth. Our results indicate 
that in the combined therapy trametinib increases CD8+ T cell infiltration in the 
tumor site and upregulates antigen presentation, and this may be associated with 
enhanced PD-L1 blockade efficacy. 
Conclusions: Our results suggest that immune evasion mechanisms in HNSCC 
could be counteracted by combination therapy with a MEK inhibitor and anti-
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Cancer immune evasion, which is characterized by disrupted antigen 
presentation and dysfunction of anti-tumor immune cells, such as cytotoxic T 
lymphocytes (1, 2), affect the carcinogenesis process, as well as metastasis and 
the recurrence of head and neck squamous cell carcinoma (HNSCC) (2, 3). To 
override the suppression of anti-tumor immune response, immune checkpoint 
inhibitors (ICIs) have been developed to target the PD-1/PD-L1 pathway that 
have shown remarkable and durable therapeutic efficacy in HNSCC (4, 5). 
However, only approximately 15-20% of patients respond to this treatment 
strategy. Therefore, additional therapies are needed that can be used in 
combination with ICIs to increase their efficacy and response rate (6). 
Several anticancer agents have been shown to modulate the immune system 
via off-target effects, suppressing tumor growth by enhancing anti-tumor 
immunity in the preclinical stages (7-12). These agents act through multiple 
mechanisms, which include i) the release of danger signals and inflammatory 
cytokines by necrotic/apoptotic cells, ii) upregulation of tumor antigen/antigen 
processing machinery components, iii) depletion or reprogramming of 
suppressive immune cell subsets, such as tumor-associated macrophage (TAM), 
myeloid-derived suppressor cell, and regulatory T cells (Tregs) and iv) 
induction of tumor infiltration by CD8+ T cells. Moreover, the effects of several 
of these anticancer agents on ICI efficacy are currently being assessed in 
clinical trials (13-15). 
Importantly, of these agents, MAPK pathway inhibitors have been reported 
to counteract immune evasion mechanisms in the tumor microenvironment, as 
oncogenic mutations in this pathway are associated with immunosuppression 
(11, 16-22). Inhibitors of components of the MAPK pathway (such as BRAF 
and/or MEK) increased the expression of tumor-associated antigen (TAA) and 
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T cell infiltration, thereby potentiating anti-tumor T cell immune responses. 
Meanwhile, PD-L1 expression appears to be variably associated with the 
MAPK pathway, depending on the experimental context; specifically, MAPK 
pathway inhibitors can up- or down-regulate PD-L1 expression in tumor cells 
(11, 17, 23). While BRAF inhibitors exert its function only in tumors with 
BRAF mutations as well as are not effective in KRAS-mutated tumors, MEK 
inhibitors do not require genetic mutations in this pathway and could overcome 
resistance induced by BRAF inhibitors. Therefore, MEK inhibitors have been 
evaluated in clinical studies for RAS- and/or RAF-mutated solid tumors in 
combination with BRAF inhibitors and these combinations have improved 
survival of patients (24). Given that studies evaluating immunomodulating 
activity of MAPK pathway inhibitors also have been done almost in melanoma 
which have frequent BRAF mutations, clinical trials evaluating the efficacy of 
a MAPK pathway inhibitor in combination with ICIs have been performed 
mostly on RAS/RAF-mutated solid cancer patients (13). 
Frequently, overexpression of EGFR and activation of its downstream 
MAPK pathway are observed in HNSCC patients, while they usually lack 
mutations in MAPK pathway (25, 26). Previous report showed that a MEK 
inhibitor, selumetinib, upregulates HLA-ABC expression and results in 
increased T-cell activation as well as IL-2 production by lymphocytes in 
papillary thyroid cancer cell lines, even in the absence of MAPK mutations (27). 
Therefore, the aim of this study was to investigate the effects of the MEK 
inhibitor on immune-related phenotypes of human HNSCC cell lines in vitro. 
Furthermore, we used a syngeneic mouse squamous cell carcinoma model 
(SCCVII) to evaluate the therapeutic efficacy of combining a MEK inhibitor 
with an anti-PD-L1 blockade. Of the most clinically studied MEK inhibitors, 
we chose trametinib which is a highly selective and the first FDA-approved 
MEK inhibitor for treatment of patients with BRAFV600E-mutated metastatic 
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MATERIALS AND METHODS 
1. Cell lines and cell culture  
Human HNSCC cell lines SNU-1041, SNU-1066, SNU-1076 cells 
(purchased from Korean Cell Line Bank, Seoul, Korea) and HN31 cells 
(obtained from John F. Ensley, Wayne State University) (28) were maintained 
in RPMI 1640 supplemented with 10% FBS and 10 µg/ml gentamycin. Detroit 
562 and FaDu cells (purchased from American Type Culture Collection, 
Manassas, VA) were maintained in EMEM supplemented with 10% FBS, 100 
U/ml penicillin and 100 µg/ml streptomycin. Murine SCC cell line SCCVII 
cells (29) were maintained in RPMI 1640 supplemented with 10% FBS, 10 mM 
HEPES, 1 mM sodium pyruvate, 10 µM MEM non-essential amino acids, 2 
mM L-glutamine, 55 µM 2-mercaptoethanol, 100 U/ml penicillin and 100 µg/ml 
streptomycin. Cell lines, except mouse SCCVII cells, were authenticated using 
PowerPlex 18D System (Promega, Madison, WI) (Table 1). All cells were 
cultured for less than three months and routinely tested for mycoplasma 
negative (Fig. 1).  
 
2. Primary T cell isolation from umbilical cord blood mononuclear cells 
(UCBMC) 
Human cord blood naive T cells were positively isolated using MACS CD3 
microbeads (Miltenyi Biotech, Bergisch Gladbach, Germany) after Ficoll 
separation. Purified cells (>95% purity) cells were suspended in RPMI 1640 
supplemented with 10% FBS and 10 g/ml gentamycin. 
 
  
2. Reagents and antibodies 
Trametinib (from Selleckchem, Houston, TX) was dissolved in DMSO for 
in vitro experiments and suspended in a mixture of 0.5% hydroxypropyl methyl  
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D5S818 9 9, 11 9, 12 11, 12 12 12, 13 
D13S317 8, 12 8, 12 8, 10 12 8, 9 11, 12 
D7S820 8, 12 12 11, 12 8, 10 11, 12 10 
D16S539 10 9, 11 13 11 11 11, 12 
vWA 14, 18 17, 18 16 16 15, 17, 18 15, 18 
TH01 7, 9 7, 8 6 8 8 7, 9 
TPOX 9, 11 8 8, 11 8, 10 11 6, 11 
CSF1PO 10 11 11, 12 11, 13 12 10, 12 
AMEL X X X, Y X  X 
D3S1358 15 17 15 
14, 15,  
16, 17 
17, 18 16 
D21S11 29 28 30 28, 30 31.2 28 
D18S51 15 19 14 15 16 13, 16 
D8S1179 12, 13 11, 16 10, 15 13 13 15, 17 
FGA 24, 25 23 24, 25 21 25 20, 24 
D2S1338 20, 22 17, 26 19, 23.3, 
24 
25 19 21, 25 
D19S433 13, 14 12.2, 14.2 15.2 14 14, 16 13 
Penta D 11 12 9, 10 13 11 2.2 
Penta E 11, 13 14, 16 12, 22 13 19 8, 12 
 







Figure 1. Cell lines are negative for mycoplasma contamination. Cell cultures 





cellulose and 0.2% TWEEN 80 for in vivo injections. For in vivo experiments, 
we used a rat anti-mouse PD-L1 monoclonal antibody (mAb) (10F.9G2) and a 
rat IgG2b isotype control (LTF-2) from BioXCell (West Lebanon, NH). Both 
the recombinant human (R&D Systems, Minneapolis, MN) and mouse IFN-γ 
(PeproTech, Rocky Hill, NJ) were reconstituted with 0.1% BSA in PBS and 
stored at -80°C before use in experiments. Phorbol myristate acetate (PMA) 
and ionomycin (Sigma, St. Louis, MO) were resolved in DMSO and stored at -
20°C before use. Primary antibodies against p-STAT1 (Tyr701), STAT1, 
STAT2, p-STAT3 (Ser727), STAT3, STAT5, p-STAT6, STAT6, p-p44/42 
MAPK (Thr202/Tyr204), p44/42 MAPK, CD274 and GAPDH (Cell Signaling 
Technology, Danvers, MA) were used for Western blotting. Antibodies against 
mouse CD8 and CD274 (Cell Signaling Technology, Danvers, MA) were used 
for immunohistochemistry (IHC). Fluorochrome-labeled mAbs for the 
following markers were used in flow cytometry: anti-human HLA-ABC (G46-
2.6), anti-human CD274 (MIH1), anti-mouse CD274 (MIH5), anti-mouse 
CD25 (PC61), anti-mouse CD8 (53-6.7), anti-mouse CD4 (RM4-5), anti-
human CXCL9 (B8-11) and anti-human CXCR3 (1C6/CXCR3) (BD 
Biosciences, San Jose, CA); anti-mouse CD45 (30-F11), anti-mouse CD3 
(eBio500A2), anti-mouse Foxp3 (NRRF-30) and anti-mouse CXCL9 (MIG-
2F5.5) (Thermo Fisher Scientific, Waltham, MA); anti-mouse H-2Kk (36-7-5), 
anti-mouse CD11b (M1/70), anti-mouse F4/80 (BM8), anti-mouse CD279 
(RMP1-30), anti-mouse Ly-6G (1A8), anti-mouse CXCR3 (CXCR3-173) and 
anti-human CXCL10 (J034D6) (BioLegend, San Diego, CA). Protein transport 
inhibitor, GolgiStop (BD Biosciences, San Jose, CA), was used to block 
CXCL9 and CXCL10 secretion for 12 hours and to block IFN- secretion for 5 





3. Cell viability assay 
A total of 2.5 x 103 cells (human cell lines) and 1.2 x 103 cells (mouse 
SCCVII cell line) per well were dispensed into 96-well culture plates. After 
cells had adhered to the plate, they were treated with trametinib for 72 hours. 
Cell growth inhibition was analyzed using the EZ-Cytox cell viability assay 
(Dogen, Seoul, Korea) and CellTiter Glo-Luminescent cell viability assay 
(Promega, Madison, WI). The absorbance was measured with a microplate 
reader (BioTek, Winooski, VT) at 450 nm for EZ-Cytox cell viability assay. 
The luminescent signal was measured with a luminescence counter (Perkin 
Elmer, Waltham, MA) for Cell Titer Glo-Luminescent cell viability assay. 
 
4. Flow cytometry 
For surface staining, cells were incubated with fluorochrome-conjugated 
mAbs for 20 minutes at 4°C. For intracellular Foxp3 staining, 
Foxp3/Transcription factor staining buffer set (Thermo Fisher Scientific, 
Waltham, MA), and for intracellular CXCL9, CXCL10 and IFN- staining, 
Fixation/Permeabilization solution kit (BD Biosciences, San Jose, CA) was 
used according to the manufacturer’s instructions. For ex vivo experiments, 
freshly isolated cells were pre-incubated with anti-mouse CD16/CD32 mAb 
(2.4G2, BD Biosciences, San Jose, CA) to block the binding of antibody to 
FcγIII/II receptor and then stained with fixable viability dye (Thermo Fisher 
Scientific, Waltham, MA) prior to antibody staining to exclude dead cells. Data 
were acquired using FACSCalibur or FACSCanto II (BD Biosciences, San Jose, 
CA) and analyzed with FlowJo software (Tree Star, Inc., Ashland, OR) 
 
5. Western blotting 
Cells were resuspended with cell lysis buffer (Cell Signaling Technology, 
Danvers, MA) containing protease inhibitor cocktail (Sigma, St. Louis, MO), 
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PMSF (Sigma, St. Louis, MO) and PhosSTOP (Merck, Kenilworth, NJ) at 4°C 
for 20 minutes. After centrifuging at 13,000 rpm at 4°C for 15 minutes, the 
supernatant was harvested. Equal amounts of proteins were separated on an 
SDS-polyacrylamide gel (Thermo Fisher Scientific, Waltham, MA) and 
transferred to PVDF membrane (Bio-Rad, Hercules, CA), which was then 
blocked with 5% skim milk at room temperature for one hour, probed with 
diluted primary antibodies at 4°C overnight, and with diluted secondary 
antibodies conjugated to HRP at room temperature for 2 hours. The signals 
were developed using ECL detection reagent (GE Healthcare, Chicago, Illinois) 
and visualized with ImageQuant LAS 4000 mini (GE Healthcare, Chicago, 
Illinois). GAPDH was used as a loading control. 
 
 
6. siRNA transfection 
SNU-1041 cells were transfected with STAT1-, STAT3-, STAT6- or non-
targeting siRNAs (Santa Cruz, Dallas, Texas) using Lipofectamine RNAiMAX 
transfection reagent (Thermo Fisher Scientific, Waltham, MA) according to the 
manufacturer’s instruction. Transfected cells were treated with trametinib for 
72 hours followed by flow cytometry and Western blotting. 
 
 
7. Quantitative real-time RT-PCR (qRT-PCR)  
Total RNA from cultured cells and mouse ex vivo isolated cells were 
extracted using RNeasy Mini Kit (Qiagen, Hilden, Germany) and reverse 
transcribed into cDNA with Superscript III first-strand synthesis system 
(Thermo Fisher Scientific, Waltham, MA). Quantification of gene expression 
was conducted using Power SYBR green PCR Master Mix and StepOnePlus 
Real-Time PCR system (Thermo Fisher Scientific, Waltham, MA). GAPDH 
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was used as an internal reference gene. Primer sequences we used are listed in 
Table 1. 
 
8. Enzyme-linked immunosorbent assay (ELISA) 
Soluble CXCL9 and CXCL10 levels in culture supernatants were measured 
using DuoSet ELISA (R&D Systems, Minneapolis, MN) according to the 
manufacturer’s instructions. 
 
9. Immunohistochemistry  
Formalin-fixed paraffin-embedded tissue sections (4 µm) were 
deparaffinized, rehydrated and subjected to heat-induced antigen retrieval with 
Tris-EDTA buffer (for PD-L1 analysis) or citrate buffer (for CD8 analysis). 
Sections were incubated in 10% normal goat serum at room temperature for 
one hour, in diluted primary antibodies at 4°C overnight, in peroxidase blocking 
solution (0.3% H2O2 in PBS) at room temperature for 15 minutes, and finally 
in diluted secondary antibodies conjugated to HRP at room temperature for 30 
minutes. Signals were developed using the DAB chromogen (Dako, Santa Clara, 
CA) and visualized with a Bright field and Fluorescence Slide Scanner (Leica, 
Wetzlar, Germany). 
 
10. In vivo SCCVII syngeneic model  
Mouse SCCVII cells (5 x 105) were injected subcutaneously into the flank 
of seven-week-old, female, C3H/HeN mice and BALB/c nude mice (Orient Bio 
Inc., Seongnam, Korea). Tumor volume was measured using a caliper and 
calculated as: (length x width2)/2. The mice were randomized to four groups 
and drug treatments began when tumor volume reached 100 ± 25 (mean ± SD) 
mm3. Trametinib (1 mg/kg) was administered by oral gavage daily, and anti-




Table 2. Primer sequences used in qRT-PCR analysis 
  
































were euthanized when tumor size exceeded 1,000 mm3. Tumors, draining 
lymph nodes (dLNs) and spleens were collected on day 5 for pharmacodynamic 
analysis. The Institutional Animal Care and Use Committee of Seoul National 
University Hospital approved all animal studies (approval number: #16-0166-
S1A1, #17-0117-S1A0 and #18-0062-S1A0). 
 
11. Statistical analysis 
Data are represented as the mean ± SD and were analyzed by GraphPad 
Prism (GraphPad Software, La Jolla, CA). An unpaired two-tailed student’s t 
test was used to determine differences between groups. All P values less than 





The MEK inhibitor trametinib increases MHC class I and PD-L1 
expression in human HNSCC cell lines with moderate cellular cytotoxicity 
We first tested the susceptibility of six human HNSCC cell lines to the MEK 
inhibitor trametinib (Fig. 2A). These cell lines do not harbor activating 
mutations in RAS or RAF with the exception of HN31, which harbor an HRAS 
G12D mutation (30). Several gene mutation profiles of each cell line we used 
were shown in Table 3. Growth inhibition by trametinib treatment occurred 
variably in these cell lines with moderate sensitivity (range of IC50: 10 nM ~ 
100 nM, in four of six cells). Based on this, we selected a sub-lethal 
concentration of trametinib (50 nM), which was used to investigate 
immunologic changes without lethal damage. As shown in Fig. 2B, trametinib 
treatment increased MHC class I expression in all cell lines. In addition, 
trametinib further enhanced exogenous IFN-γ-induced MHC class I 
upregulation. We also observed that trametinib slightly increased basal and 
IFN-γ-induced PD-L1 expression in all cell lines, except in SNU-1066, in 
which trametinib treatment diminished IFN-γ-induced PD-L1 upregulation (Fig. 








Figure 2. Trametinib exerts moderate cytotoxic effect on human HNSCC cell lines 
and increases MHC class I and PD-L1 expression in surviving cells. A, Cells were 
incubated with 10 pM - 10 µM of trametinib for 72 hours and cell growth inhibition 
was analyzed using a cell viability assay. Data are shown as the mean ± SD from three 
independent experiments. B, C, Cells were treated with trametinib (50 nM), IFN-γ (1 
ng/ml; 10 ng/ml to examine PD-L1 expression in SNU-1066 cells) or the combination 
of trametinib and IFN-γ (pretreated with DMSO or trametinib one hour prior to the 
addition of IFN-γ) for 72 hours. Expression of MHC class I (B) and PD-L1 (C) were 
assessed by flow cytometry. The fold change in mean fluorescence intensity (MFI) was 
averaged from three independent experiments. Error bars indicate SD. D, Changes in 
PD-L1 expression shown in Fig. 2C were confirmed by Western blotting. Data show 









TP53 p.G245D Substitution_missense 
BRCA2 p.G2063E Substitution_missense 
SNU-1066 
TP53 p.G187_splice Deletion_Frameshift 
CDKN2A p.D92fs*54 Deletion_Frameshift 
STAT1 p.K209R Substitution_missense 
JAK1 p,L50V Substitution_missense 
TGFBR2 p.S409F Substitution_missense 
APC p.E601D Substitution_missense 
IDH2 p.Q64H Substitution_missense 
SNU-1076 
TP53 p.KSVT120fs Deletion_Frameshift 
CDKN2A p.P114H Substitution_missense 
PIK3CA p.H1047R Substitution_missense 











BRCA2 p.Q861_fs Insertion_frameshift 
ERBB3 p.D297H Substitution_missense 
TGFA p.A37T Substitution_missense 
RAF1 p.P614L Substitution_missense 
ROS1 p.Y2114C Substitution_missense 
HN31 
TP53 p.C176F Substitution_missense 
HRAS p.G12D Substitution_missense 
CDKN2A p.M54fs*61 Deletion_frameshift 
 
 
Table 3. Several mutational characteristics in oncogenes and tumor 
suppressor genes (TSGs) of human HNSCC cell lines. Oncogenes and TSGs 





Upregulation of MHC class I and PD-L1 by trametinib is STAT3-
dependent 
Next, we investigated the effects of trametinib on STAT signaling pathway, 
as it is known to regulate MHC class I and/or PD-L1 expression (31-34). First, 
we confirmed that trametinib suppresses Erk1/2 phosphorylation at a 
concentration of 50 nM we used (Fig. 3A). When we assessed change in STAT 
phosphorylation upon trametinib and IFN-γ treatment, except for STAT4, 
whose expression is restricted to myeloid cells, thymus and testes, we found 
that treatment with trametinib increased p-STAT1 expression, and this effect 
was enhanced in the presence of exogenous IFN-γ (Fig. 3B). While total 
STAT1 expression was low, expression was increased after IFN-γ treatment, 
via input from a positive feedback loop, and this was further enhanced by 
trametinib in some cells. Furthermore, trametinib treatment activated STAT3 
and STAT6 was shown to be activated by trametinib treatment in three of six 
cell lines. Phosphorylated STAT2 and STAT5 were not detected in any 
condition of any cell line we used (data not shown).  
To determine which signaling molecule was responsible for the 
upregulation of MHC class I and PD-L1 by trametinib, we knocked down 
STAT1, STAT3 and STAT6 expression with siRNA transfections. For these 
experiments, we used SNU-1041 cells, as the change in MHC class I and PD-
L1 expression was most prominent in these cells (Fig. 2B-D). After confirming 
that each STAT expression was efficiently and specifically downregulated at 
the protein level (Fig. 4A), we found that, interestingly, STAT3 knock-down, 
but not STAT1 or STAT6, abolished trametinib-induced MHC class I and PD-
L1 upregulation (Fig. 4B). We observed that STATs were not involved in these 






Figure 3. Trametinib increases STAT1, STAT3 and STAT6 phosphorylation while 
inhibiting Erk1/2 pathway in human HNSCC cell lines. A, Human HNSCC cell 
lines were treated with the indicated doses of trametinib. After 24 hours, expression of 
phospho- and total-Erk1/2 were assessed by Western blotting. Representative images 
from two independent experiments are shown. B, Cells were treated with trametinib 
(50 nM), IFN-γ (1 ng/ml) or the combination of trametinib and IFN-γ (pretreated with 
DMSO or trametinib one hour prior to the addition of IFN-γ) for 72 hours. Levels of p-
STAT1, p-STAT3 and p-STAT6 were examined by Western blotting. Data are 








Figure 4. STAT3 depletion abolishes the effect of trametinib on MHC class I and 
PD-L1 expression in SNU-1041 cells. A, SNU-1041 cells were transfected with 
siControl, siSTAT1, siSTAT3 or siSTAT6. Expression of all STAT family members, 
except STAT4, was examined by Western blotting in untransfected (No Tfx), siControl, 
siSTAT1, siSTAT3 or siSTAT6 transfectants, respectively. Representative Western 
blot from three independent experiments were shown. B, SNU-1041 cells were 
transfected as in (A). MHC class I and PD-L1 expression were analyzed in siRNA-
transfected cells after trametinib treatment for 72 hours using flow cytometry. top; bar 
graphs showing the fold change in MFI from three independent experiments (error bars 
indicate SD), bottom; representative histogram showing unstained (dashed line), 




T cell-recruiting chemokines CXCL9 and CXCL10 are upregulated by 
trametinib, which synergizes with IFN-γ in human HNSCC cell lines 
Increased antigen presentation through MHC class I molecules can be 
recognized by CD8+ T cells when they are present within the tumor 
microenvironment. Therefore, we next examined trametinib’s effects on levels 
of the T cell chemoattractants CXCL9 and CXCL10, which are also induced by 
IFN-γ, in human HNSCC cell lines. As we expected, trametinib treatment 
significantly induced CXCL9 and CXCL10 mRNA expression (Fig. 5A and B) 
as well as protein expression (Fig. 5C, D and Fig. 6). Moreover, chemokine 
expression was even further increased by combined exposure to both trametinib 
and exogenous IFN-γ. These in vitro findings suggest that trametinib treatment 
facilitates anti-tumor immunity by increasing T cell infiltration and antigen 
presentation in the tumor; however, PD-L1 blockade is also required, as 









Figure 5. Trametinib enhances T cell chemoattractants level and synergizes with 
IFN-γ in human HNSCC cell lines. Cells were treated with trametinib (50 nM), IFN-
γ (5 ng/ml) or the combination of trametinib and IFN-γ (pretreated with DMSO or 
trametinib one hour prior to the addition of IFN-γ) for 72 hours. Expression of CXCL9 
(A) and CXCL10 (B) were determined by qRT-PCR. Results represent gene expression 
changes in log10 scale ± SD of three independent experiments. Protein levels of 
CXCL9 (C) and CXCL10 (D) were measured in culture supernatants by ELISA. Data 








Figure 6. Trametinib upregulates CXCL9 and CXCL10 protein expression and 
synergizes with IFN-γ in human HNSCC cell lines. Cells were treated with 
trametinib (50 nM), IFN-γ (5 ng/ml) or the combination of trametinib and IFN-γ 
(pretreated with DMSO or trametinib one hour prior to the addition of IFN-γ) for 72 
hours. Expression of CXCL9 and CXCL10 were assessed by intracellular flow 
cytometry after treatment with GolgiStop for the last 12 hours of 72 hours. A, B, The 
fold change in percentage of cells expressing CXCL9 (A) and CXCL10 (B) was 
averaged from three independent experiments. C, D, The fold change in MFI level for 
CXCL9 (C) and CXCL10 (D) was averaged from three independent experiments. Error 




Trametinib exhibited similar effects in an SCCVII mouse cell line 
Prior to investigating the therapeutic efficacy of combining trametinib with 
an anti-PD-L1 mAb in an SCCVII mouse squamous cell carcinoma model, we 
validated our human HNSCC cell lines observations in SCCVII mouse cells. 
Trametinib treatment moderately inhibited cell growth with an IC50 value of 10 
± 1.2 nM (Fig. 7A). In addition, we found that expression of the MHC-encoded 
class I molecule H-2Kk was highly induced in live cells in the presence of 
trametinib, whereas expression of PD-L1 was not changed (Fig. 7B). However, 
trametinib synergistically induced both PD-L1 and H-2Kk expression in the 
presence of exogenous IFN-γ.  
Interestingly, expression of CXCL9 and CXCL10 was elevated by 
trametinib with or without IFN-γ (Fig. 7C and D). Erk1/2 activation was 
suppressed at the concentration of trametinib we used (Fig. 7E). Therefore, we 
concluded that the SCCVII tumor model was an appropriate model to test our 
hypothesis, as we found that trametinib increased the antigenicity and 
immunogenicity of tumor cells by upregulating MHC class I, CXCL9 and 
CXCL10. However, the concurrent induction of PD-L1 indicated that co-







Figure 7. In vitro evaluation of the immunomodulating activity of trametinib in an 
SCCVII mouse cell line. A, SCCVII cells were incubated with 10 pM – 10 µM of 
trametinib for 72 hours and cell growth inhibition was determined using a cell viability 
assay. Data are the mean ± SD from three independent experiments. B-D, SCCVII cells 
were treated with trametinib (30 nM), IFN-γ (1 ng/ml, B; 5 ng/ml, C and D) or the 
combination of trametinib and IFN-γ (pretreated with DMSO or trametinib one hour 
prior to the addition of IFN-γ) for 72 hours. B, The expression of H-2Kk (left) and PD-
L1 (right) was assessed by flow cytometry. The fold change in MFI was averaged from 
three independent experiments. Error bars indicate SD. C, Changes in CXCL9 and 
CXCL10 gene expression were determined by qRT-PCR. Data show the mean ± SD 
from three independent experiments in log10 scale. D, CXCL9 protein levels were 
analyzed by intracellular flow cytometry after treatment with GolgiStop for the last 12 
hours of 72 hours. The fold change in percentage of cells expressing CXCL9 was 
averaged from three independent experiments. Error bars indicate SD. E, Cells were 
treated with the indicated doses of trametinib. After two hours, the expression of 
phospho- and total-Erk1/2 was assessed by Western blotting. Data show one of three 
independent experiments with comparable results. 
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Combined therapy with trametinib and an anti-PD-L1 mAb delays mouse 
tumor growth and increases the number of CD8+ tumor-infiltrating T cells 
To investigate the in vivo efficacy of a combined therapy, compared to each 
treatment alone, SCCVII cells were implanted subcutaneously in the flank of 
C3H syngeneic mice. We found that the trametinib dose used was sufficient to 
inhibit Erk1/2 activation in tumor tissues (Fig. 8A). However, as shown in Fig. 
8B, trametinib treatment alone did not delay tumor growth, and anti-PD-L1 
mAb monotherapy was also ineffective. In contrast, concurrent combination 
treatment with trametinib and an anti-PD-L1 mAb resulted in a delay of tumor 
growth. 
Analysis of immune subsets within the tumor microenvironment on the fifth 
day after treatment revealed an increase in infiltrating CD8+ T cells in 
trametinib-treated mice (Fig. 9A and B). CD3+CD4+CD25+Foxp3+ Treg cells 
were slightly decreased by trametinib treatment, but this was not statistically 
significant. TAMs (CD11b+F4/80+) were not affected by any treatments. The 
number of neutrophils (CD11b+Ly6G+) was decreased by exposure to an anti-
PD-L1 mAb, both with or without trametinib. Increased CD3+CD8+ tumor 
infiltrating lymphocytes (TILs) were found in mice that received the combined 
trametinib and an anti-PD-L1 mAb treatment, and this was correlated with 
longer survival, while there were no significant alterations in other immune 
subsets (Fig. 10). 
The T cell activation marker CD25 was elevated in CD8+ T cells by 
trametinib treatment (Fig. 11A), and this was also associated with the longer 
survival observed in mice who received the combination therapy (Fig. 11B). 
Other activation markers, PD-1, CD69 and T-bet, showed no significant 
difference between groups (Fig. 11A). To assess the ability of CD8+ T cells to 
produce IFN-, CD8+ T cells isolated from tumor tissue and spleen (and 
draining lymph nodes (dLNs) at the endpoint analysis), respectively, were 
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stimulated with PMA and ionomycin ex vivo. At early phase, trametinib alone 
or when combined with an anti-PD-L1 mAb slightly inhibited the production 
of IFN- from CD8+ T cells (Fig. 12A). However, we observed that IFN- 
production was increased by trametinib treatment and it was further enhanced 
by combination with an anti-PD-L1 mAb at the endpoint (Fig. 12B). 
Interestingly, treatment with an anti-PD-L1 mAb resulted in a decrease in the 
total T cells, an increase in CD25+– and PD-1+– T cells, and an increased 
proportion of Treg cells in CD4 T cells in the secondary lymphoid organs, 
whereas trametinib-induced immunological changes were limited to tumor sites 
(Fig. 13). This indicates that treatment with an anti-PD-L1 mAb regulated 
systemic immunity. We did not observe any adverse effects associated with 
immune activation from any of the treatments. 
Finally, we confirmed our in vitro findings in vivo, five days after treatment. 
Consistent with the in vitro data, the mRNA expression of H-2Kk, as well as its 
associated molecule β2m, were increased by trametinib treatment (Fig. 14A). 
CXCL9 and CXCL10 transcripts tended to be increased by trametinib and/or 
anti-PD-L1 mAb treatment, despite variations among mice. As expected, 
expression of CXCR3, which is a receptor for CXCL9 and CXCL10, increased 
in splenic T cells after treatment with an anti-PD-L1 mAb, which activate 
systemic immunity as observed in Fig. 13, because CXCR3 expression is highly 
increased in activated T cells (Fig. 15A and B) (35). Meanwhile, trametinib was 
not shown to be involved in increasing CXCR3 expression, but at least to have 
no negative effects either alone or in combination with an anti-PD-L1 mAb. In 
more detail, we analyzed CXCR3 expression in naive T cell subset derived from 
umbilical cord blood mononuclear cells (UCBMCs), since adult peripheral T 
cells are mixed with different subsets of T cells depending on their activation 
status. As shown in Fig. 16, the expression of CXCR3 was increased by 
trametinib treatment in naive T cells including both CD4+ and CD8+ T cells. An 
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increase in PD-L1 expression in trametinib-treated mice was also observed (Fig. 
14A, B and Fig. 17A). The specificity of PD-L1 IHC was investigated using 
spleens from naïve and tumor-bearing mice (Fig. 17B). When we performed 
the same experiment as in Fig. 8B using T cell-deficient BALB/c nude mice, 
there was no tumor growth retardation by the combination of trametinib and an 
anti-PD-L1 mAb, demonstrating it was attributed to T cells consistent with the 
above results (Fig. 18). These data indicate that trametinib-induced 
immunological changes enhance CD8+ T cell responses; however, blockade of 







Figure 8. Anti-tumor activity of combined treatment with trametinib and an anti-
PD-L1 mAb in an SCCVII syngeneic mouse tumor model. A, Tumor-bearing C3H 
mice (n=3) received trametinib by oral gavage once daily at the indicated doses. 
Inhibition of Erk1/2 activation was determined by Western blotting at the endpoint. B, 
Tumor-bearing C3H mice (n=5-6) were treated with trametinib (1 mg/kg) by oral 
gavage once daily and/or anti-PD-L1 mAb (10 mg/kg) by intraperitoneal (i.p.) injection 






Figure 9. Trametinib treatment with or without an anti-PD-L1 mAb increases 
CD8+ T cell infiltration in the tumor site after five days of treatment. A, Immune 
subsets constituting tumor tissue were analyzed using flow cytometry (n=4). Cells were 
subjected first to gating to eliminate debris, doublets and dead cells, and further 
analyzed by gating CD45+ cells. B, CD8+ T cells within tumor tissues were assessed by 







Figure 10. Treatment with trametinib and an anti-PD-L1 mAb specifically 
increases CD8+ T cells, which is associated with delayed tumor growth. Immune 
cell subsets were analyzed using flow cytometry after gating CD45+ cells at the 
endpoints (n=2-4). Graphs represent each immune cell subset from individual mice 








Figure 11. Expression of CD25 is increased by trametinib treatment with or 
without an anti-PD-L1 mAb and associated with delayed tumor growth by 
combination treatment. A, B, Levels of the activation markers including CD25 were 
measured in tumor-infiltrating CD8+ T cells using flow cytometry after five days of 
treatment (n=4) (A) and only CD25 at the endpoint (n=2-4) (B). B, Graphs represent 









Figure 12. Trametinib enhances the ability of CD8+ T cells to produce IFN- at 
later stage of tumor progression. Cells isolated from each tissue after five days of 
treatment (n=4) (A) and at the endpoint (n=2-4) (B) were stimulated with PMA (10 
ng/ml) and ionomycin (1 g/ml) ex vivo for 6 hours. To block the secretion of IFN-, 
GolgiStop was treated after one hour of treatment with stimuli. IFN- production from 






Figure 13. The effects of trametinib on T cells were confined to the tumor tissue, 
whereas the anti-PD-L1 mAb acted systemically. T cell composition and expression 
of their activation markers within the tumor-draining lymph node (A) and spleen (B) 







Figure 14. Confirmation of in vitro findings in vivo five days after treatment. A, 
Transcript levels of immune-related molecules were measured by performing qRT-
PCR (n=4). B, Representative IHC images show PD-L1 expression within tumor tissue 





Figure 15. An anti-PD-L1 mAb enhances CXCR3 expression in splenic T cells. 
CXCR3 expression in splenic T cells was analyzed using flow cytometry after five days 
of treatment (A) (n=4) and at the endpoint (B) (n=4-7; sequential administration of 
drugs as in Fig. 17). B, Graphs represent CXCR3 expression from individual mice over 






Figure 16. Trametinib upregulates CXCR3 expression in naive T cell subset 
derived from UCBMC. CXCR3 expression in naive T cells was analyzed using flow 
cytometry after three (top) and five days (bottom) of treatment with trametinib. The 









Figure 17. Results of PD-L1 immunohistochemistry at 400 X magnification. A, 
Higher magnification of PD-L1 IHC shown in Fig. 13B. B, Staining results of relevant 
controls. Spleens from naïve (top) and tumor-bearing (bottom) mice were stained with 







Figure 18. Same experiment as in Fig. 8B using BALB/c nude mice. A, Tumor-
bearing BALB/c nude mice (n=5) were treated with trametinib (1 mg/kg) by oral 
gavage once daily and/or anti-PD-L1 mAb (10 mg/kg) by intraperitoneal injection 




Sequential treatment of trametinib and an anti-PD-L1 mAb inhibited 
tumor growth in a manner similar to the concurrent administration 
Finally, we changed the treatment schedule from concurrent administration 
to sequential treatment to evaluate the immunomodulating effect of trametinib 
followed by an anti-PD-L1 mAb therapy. Trametinib treatment was given when 
the tumor grew to be palpable (at day -5), and an anti-PD-L1 mAb was 
administered five days later (day 0). However, we found that sequential 
treatment did not improve the effect on tumor growth, compared with 
concurrent administration (Fig. 19A). Moreover, similar to the previous 
experiments, trametinib or anti-PD-L1 mAb alone had no benefits in tumor 
control, and delayed tumor growth was seen only when they were combined. 
Again, overall immunological changes following combined therapy, including 
increased CD8+ T cell infiltration in the tumor, were the same from endpoint 
analysis (Fig. 19B). It was demonstrated that, in this murine squamous cell 
carcinoma model, combining trametinib and an anti-PD-L1 mAb is a more 
potent intervention than either treatment alone, regardless of treatment 





Figure 19. Sequential administration of trametinib and an anti-PD-L1 mAb 
inhibited tumor growth and increased T cell infiltration in a similar pattern as the 
concurrent administration. A, Tumor-bearing C3H mice (n=5-7) were given 
trametinib (day -5) and then an anti-PD-L1 mAb five days later (day 0). B, Cells were 
isolated from tumor tissues (n=4-7) for measuring of each immune cell subset at the 
endpoints. Graphs represent each immune cell subset from individual mice over time 






In this study, we found that treatment with the MEK inhibitor trametinib 
increases the expression of IFN-γ-induced immune molecules, including MHC 
class I, PD-L1, CXCL9 and CXCL10, which are associated with anti-tumor 
immunity. Inefficient tumor antigen presentation and recognition, through the 
loss or downregulation of MHC class I molecules on tumor cells is a well-
known immune evasion mechanism. Although recent advances in anti-PD-
1/PD-L1 blocking immunotherapies have shown remarkable clinical benefit, 
there are many non-responders as well as relapsed patients associated with 
downregulated MHC class I expression (36, 37). When tumors harbor 
alterations involved in antigen processing and presentation, several strategies 
can be explored to restore their expression (38, 39), including epigenetic 
modulation, IFN-γ pathway activation and inhibition of oncogenic signaling. In 
HNSCC, expression of MHC class I and β2m is also downregulated mostly in 
a reversible manner (40). Here, we demonstrated that the MEK inhibitor 
trametinib increases MHC class I expression at a concentration with moderate 
cellular cytotoxicity in human HNSCC cell lines. Simultaneous upregulation of 
PD-L1 expression by trametinib, with or without IFN-γ, was also observed in 
most cell lines tested. 
MHC class I and PD-L1 are well-known downstream targets of IFN-γ 
signaling through the STAT1 pathway (31). PD-L1 expression is also regulated 
by various signaling pathways, including PI3K/Akt, MAPK, STAT3 and NF-
κB pathways, both intrinsically (congeneric) and extrinsically (interaction with 
stromal cells) (41). Trametinib treatment acts through both the STAT1 and 
STAT3 pathways regulating MHC class I and PD-L1 expression. To this end, 
we found that trametinib-induced STAT3 activation upregulated MHC class I 
and PD-L1 in the SNU-1041 cell line. It is noteworthy that STAT3 is involved 
in the upregulation of MHC class I expression, because many signals involved 
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in immune suppression and tumor promotion are associated with STAT3 
activation (42, 43). STAT3 is classically known to play an opposing role to 
STAT1- and NF-B-mediated T helper type 1 immune responses, which are 
major transcriptional activators of MHC class I (44). However, these pathways 
are mechanistically interconnected with each other in a highly context-
dependent manner. As an example, NF-B pathway is responsible for both 
inflammation-induced tumorigenesis and anti-tumor immune response by 
regulating the expression of multiple inflammatory mediators and also could be 
activated by STAT3 signaling (45). Although the present study was able to 
obtain only implication for the relevance of STAT3 pathway in these 
phenomena, the underlying mechanism needs to be further deeply investigated 
for each cell line. 
Based on the presence of effectors (CD8+ T cells) and suppressors (PD-L1+ 
cells), tumor microenvironments can be classified into four categories (46, 47). 
Using this classification system, type II (TIL-PD-L1-) and III (TIL-PD-L1+) 
tumors are predicted to respond poorly to anti-PD-1/PD-L1 mAb therapy. 
Therefore, it is important to attract CD8+ T cells to tumors, as this may increase 
the therapeutic efficacy of immune checkpoint blockade therapies such as anti-
PD-1/PD-L1 mAbs. Here, we observed that trametinib increases the expression 
of T cell recruitment chemokines (CXCL9 and CXCL10) in all human HNSCC 
cell lines examined, which may be further substantiated in the presence of T-
cell derived IFN-γ. 
We inferred that CD8+ T cells mediate the functions of drugs by estimating 
the changes in total tumor-infiltrating CD8+ T cells irrespective of antigen 
specificity because the mouse SCCVII tumor model lacks known TAAs. 
Despite a paucity of the specific TAA, the observed correlations between 
delayed tumor growth and the indicative of T cell activation, CD25, and IFN- 
production from ex vivo isolated T cells suggest that increased CD8+ T cell 
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infiltration might contribute to suppress tumor progression. However, another 
issue is that there could be treatment-related toxicities because we do not 
currently know where the CD8+ T cell response is directed. Although we did 
not observe toxicity defined by weight loss, appearance, behavior and mortality 
in any group of treatments in this study, severe side effects are occasionally 
observed in patients in clinic (data not shown), reflecting more detailed 
mechanisms of the drug action should be further investigated.  
In addition, this was not the first study to evaluate the efficacy of a combining 
a MAPK pathway inhibitor and an anti-PD-1/PD-L1 mAb to enhance anti-
tumor immune responses. However, our study is still meaningful in that most 
previous reports have examined this combination in MAPK mutant systems (19, 
20, 48). Moreover, combination therapies using a MEK inhibitor and an anti-
PD-1/PD-L1 mAb that are being examined in active clinical trials are primarily 
being performed in patients with BRAF mutant melanoma and KRAS mutant 
lung and colorectal cancer (NCT01988896). Recently, unlike expectations from 
phase Ib clinical trial, which shows encouraging tolerability and clinical 
activity in patients with colorectal cancer, expanding phase III trial, IMblaze370, 
did not meet its primary endpoint (NCT02788279). Several possible 
explanations for this failure might include: i) other co-stimulatory/-inhibitory 
molecules should be co-targeted to reach maximum T-cell activity (49, 50), ii) 
suppressive immune subsets like TAMs could mediate resistance to treatments 
(51-53). In current study, macrophages constituted substantial proportion in 
tumor tissues and the role of this subset as well as of other suppressive cells 
like Tregs need to be assessed to improve the drug efficacy. iii) Lastly, there 
could be a immunoregulatory role of the patient’s microbiota, recently being 
proven to influence the anti-PD-1/PD-L1 mAb efficacy (54). 
Based on our results, we propose that the combination of a MEK inhibitor 
and an anti-PD-1/PD-L1 mAb would be therapeutically beneficial for HNSCC 
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patients without MEK pathway mutations. Since immunotherapy still holds 
much promise, it is important to understand precise mechanisms behind the 
resistance to these therapies in future. In addition, further immunological 
studies using other small molecule inhibitors, especially those that target non-
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연구 목적: 현재 종양 면역 회피에 대한 이해의 진보는 두경부암을 포함한 암 
치료에 있어서 면역 요법의 새로운 분야를 이끌어 내었다. 그러나 여전히 
소수의 환자만이 항 PD-1/PD-L1 단일 클론 항체에 반응을 보인다. 본 
연구에서는, 인간 두경부암 세포주에서 면역 관련 분자인 MHC class I, PD-
L1 및 T 세포 유인 케모카인인 CXCL9 및 CXCL10 의 발현에 대한 MEK 
억제제인 trametinib 의 효과를 조사했다. 그런 다음 우리는 두경부암을 위한 
모델인 SCCVII 마우스 동종 종양 모델을 사용하여 생체 내에서 항 PD-L1 
단일 클론 항체와 병용한 trametinib 의 치료 효능을 평가했다. 
연구 방법: 6 개의 인간 두경부암 세포주 (SNU-1041, SNU-1066, SNU-
1076, Detroit 562, FaDu 및 HN31) 및 마우스 편평 세포암 세포주 
(SCCVII)를 사용하였다. 우리는 이 세포주를 사용하여 trametinib 처리 후 
72 시간 뒤에 MTT 세포 생존율 분석을 수행했다. MHC class I 및 PD-L1 
발현 수준은 trametinib 및 인터페론 감마를 처리한 후 유세포 계측법으로 
분석하였다. PD-L1, Erk1/2, STAT1, STAT2, STAT3, STAT5 및 
STAT6 의 발현은 웨스턴 블롯으로 분석하였다. STAT1, STAT3 및 
STAT6 를 리포펙타민을 사용하는 siRNA 주입에 의해 유전자 발현 억제 
시켰다. Trametinib 처리 후 CXCL9 및 CXCL10 전사체의 발현 수준을 
확인하기 위해 정량적 실시간 PCR 이 수행되었다. ELISA 및 유세포 분석법을 
사용하여 CXCL9 및 CXCL10 의 단백질 수준을 결정하였다. 동종 마우스 
SCCVII 편평 세포암 모델에서 MEK 억제제와 항 PD-L1 단일 클론 항체의 
병용 치료 효과를 평가하였다. 
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연구 결과: Trametinib 에 의한 성장 억제는 적정한 감도 (6 개의 인간 세포 중 
4 개에서의 IC50 값이 10 nM 이상, 100 nM 이하)로 세포주 간에 가변적이었다. 
Detroit 562 와 FaDu 에서의 IC50 값은 10 μM 이상이었다. Trametinib 은 인간 
두경부암 세포주에서 MHC class I 과 PD-L1 발현을 상향 조절하였으며, 이는 
STAT3 활성화를 통해 일어났다. 또한, trametinib 은 인간 두경부암 
세포주에서 종양 조직으로의 T 세포 침윤과 연관되고, 인터페론 감마에 의해 
증가하는 CXCL9 과 CXCL10 의 발현을 상향 조절했다. 마지막으로, 우리는 
두경부암을 위한 SCCVII 동종 종양 모델을 사용하여 생체 내에서 항 PD-L1 
단일 클론 항체와 조합된 trametinib 의 치료 효능을 평가하였다. PD-L1 
차단이나 trametinib 치료는 각각 단독으로는 종양 성장에 영향을 미치지 
않았지만, 병용 치료 시에 종양 성장을 유의하게 지연시켰다. 우리의 결과는 이 
병용 치료에서 trametinib 이 종양 부위로의 CD8+ T 세포 침윤을 증가시키고 
항원 제시를 증가시키는 것을 보여주었으며, 이는 PD-L1 차단 효능의 증강과 
연관될 수 있음을 보여주었다. 
결론: 우리의 결과는 두경부암에서의 면역 회피 기전이 MEK 억제제와 항 
PD-1/PD-L1 단일 클론 항체의 병용 요법에 의해 상쇄됨으로써 종양 성장이 
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